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Abstract
Background—Myocardial fibrosis is a feature of many cardiac diseases. We used proteomics to 
profile glycoproteins in the human cardiac extracellular matrix (ECM).
Methods—Atrial specimens were analyzed by mass spectrometry after extraction of ECM 
proteins and enrichment for glycoproteins or glycopeptides.
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Results—ECM-related glycoproteins were identified in left and right atrial appendages from the 
same patients. Several known glycosylation sites were confirmed. In addition, putative and novel 
glycosylation sites were detected. Upon enrichment for glycoproteins, peptides of the small 
leucine-rich proteoglycan decorin were consistently identified in the flow through. Out of all ECM 
proteins identified, decorin was found to be most fragmented. Within its protein core, eighteen 
different cleavage sites were identified. In contrast, no cleavage was observed for biglycan, the 
most closely related proteoglycan. Decorin processing differed between human ventricles and atria 
and was altered in disease. The C-terminus of decorin, important for the interaction with 
connective tissue growth factor, was predominantly detected in ventricles compared to atria. In 
contrast, atrial appendages from patients in persistent atrial fibrillation had higher levels of full-
length decorin but also harbored a cleavage site that was not found in atrial appendages from 
patients in sinus rhythm. This cleavage site preceded the N-terminal domain of decorin that 
controls muscle growth by altering the binding capacity for myostatin. Myostatin expression was 
decreased in atrial appendages of patients with persistent atrial fibrillation and hearts of decorin 
null mice. A synthetic peptide corresponding to this decorin region dose-dependently inhibited the 
response to myostatin in cardiomyocytes and in perfused mouse hearts.
Conclusions—This proteomics study is the first to analyse the human cardiac ECM. Novel 
processed forms of decorin protein core, uncovered in human atrial appendages can regulate the 
local bioavailability of anti-hypertrophic and pro-fibrotic growth factors.
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Introduction
The importance of the ECM is increasingly being recognized, gradually overturning the 
concept that the cardiac ECM is inert. ECM proteins account for physiological properties of 
the cardiac tissue but also contribute to fibrosis and hypertrophy in disease. Fibrosis involves 
structural proteins but also matricellular proteins, predominantly glycoproteins. Due to the 
continuous need for dynamic adaptation in the heart, matricellular proteins are of particular 
importance. Previous studies have demonstrated that ECM deposition facilitates the 
development of ectopic pacemakers and late potentials as a result of inhomogeneous 
stimulus conduction, and can also lead to fluctuations in membrane potential.1 Thus, atrial 
fibrotic remodeling has been implicated as a potential therapeutic target in atrial fibrillation 
(AF).2
Proteomics offers the ability to quantify multiple proteins simultaneously without the 
constraints of antibodies. Most proteomics studies, including the ones on AF, investigated 
the cellular proteome. 3,4 We have previously developed a sequential extraction procedure to 
reduce cellular proteins before studying ECM remodelling in a porcine model of ischemia/
reperfusion injury.5 No proteomics study has been conducted on the human cardiac ECM.
Therefore, the aims of the present study were fourfold: i) to provide a comprehensive 
characterisation of ECM proteins in human atrial appendages; ii) to interrogate protein 
glycosylation of matricellular proteins; iii) to explore regional differences in the cardiac 
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ECM composition; and iv) to interrogate ECM remodelling in the context of AF. We 
discovered extensive cleavage in the protein core of the proteoglycan decorin, a key 
constituent of the cardiac microenvironment. Decorin is a member of the small leucine-rich 
proteoglycan family (SLRPs)6,7 and regulates collagen fibrillogenesis as well as a variety of 
other ECM molecules involved in cell signalling.8 Processed forms of decorin detected in 
the human cardiac ECM had myostatin and connective tissue growth factor (CTGF) binding 
properties that might contribute to the pathophysiology of AF by regulating the 
bioavailability of growth factors.
Methods
An expanded Methods section is available in the online data supplement at http://
circ.ahajournals.org.
Human cardiac tissue
All procedures involving use of human tissues were approved by the local Regional Ethics 
Committee Board. Written informed consent was obtained from all patients (n=65). Atrial 
samples were collected from patients undergoing cardiac surgery at St. George’s School of 
Medicine (London, United Kingdom, REC number (06/Q0803/69) corresponding to 
EudraCT number: 2006-005272-40). Atrial tissue was obtained from the atrial appendages 
during cardiopulmonary bypass and just after cardioplegic arrest of the heart.4
ECM extraction
ECM protein enrichment was performed using our previously published 3-step extraction 
method, involving sequential incubation with 0.5M NaCl for 1 hr, 0.1% SDS for 16 hrs and 
a final incubation for 48 hr with 4M guanidine hydrochloride (GuHCl).5 Matched samples 
from both atria (n=5) were further enriched in ECM glycoproteins using a lectin-binding 
based protocol (i.e. wheat germ agglutinin and concanavalin A). GuHCl extracts (input), 
glycoprotein-enriched extracts and the flow-through were enzymatically deglycosylated. Gel 
electrophoresis for deglycosylated proteins was performed using 4-12% Bis-Tris gradient 
gels. Gels were fixed and silver stained. The entire gel lanes were excised and digested using 
trypsin.5 For direct glycopeptide identification, proteins were digested in solution without 
deglycosylation.
Mass spectrometry analyses
Liquid chromatography (LC) tandem mass spectrometry (MS/MS) acquisition was 
performed as previously described.9 MS/MS peak lists were matched to a human database 
using Mascot (version 2.3.01, Matrix Science). Two missed trypsin cleavages were allowed. 
An additional, “no enzyme” search was performed to identify peptides derived from non-
tryptic cleavages. For the identification of the glycosylation sites, a direct glycopeptide 
strategy was pursued using a combination of different fragmentation modes on an Orbitrap 
Elite MS as published elsewhere.10
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P(CAGA)12-luciferase reporter assay
HEK293 cells (ATCC) were transfected with the pGL3(CAGA)12 reporter plasmid. 
Recombinant mouse myostatin was added at a final concentration of 2.5nM ± decorin N-
terminal peptides at different concentrations.11 The HEK293 cells were cultured for 24 hrs 
and were then lysed and luciferase activity was assayed.
Proton nuclear magnetic resonance (+H-NMR) spectroscopy
Metabolites from mouse cardiac tissue were extracted using a methanol-based procedure. 
NMR spectra were acquired on a 700 MHz Bruker spectrometer using 9.3 kHz spectral 
width and 32 K data points with acquisition time of 1.67 s, relaxation delay of 5 s and 128 
scans. The resulting spectra were processed to 65536 data points and corrected for phasing 
and zero referencing using NMRLab software.
Functional experiments
To test the biological effects of decorin peptides, neonatal rat cardiomyocytes were used for 
in vitro experiments, and hearts from 10-12 week-old C57BL/6J male mice were perfused in 
a Langendorff system. Details are given online.
Statistical analysis
Clinical characteristics are summarized as mean ± standard deviation (SD) or as 
percentages, and tested for differences across groups using unpaired t-tests for unequal 
variances or Fisher’s exact tests. For all significance testing, a two-tailed p<0.05 was 
deemed significant.
Results
Glycoproteomic characterization of the ECM in human atria
Atrial appendages were obtained from patients undergoing coronary artery bypass grafting. 
The clinical characteristics and average atrial sizes of the patient cohort (n=14) are 
summarized in Table I in the online-only Data Supplement. ECM protein extracts were 
prepared as previously described5 and analysed using a high mass accuracy tandem mass 
spectrometer (Figure 1A). All identified extracellular proteins are listed in Table II in the 
online-only Data Supplement.
We also obtained left and right atrial appendages (LAA and RAA) from the same patients 
undergoing cardiac surgery (n=5 each) and added enrichment steps for glycoproteins and 
glycopeptides (Figure 1A). Peptides belonging to glycoproteins doubled upon enrichment 
for glycoproteins (Figure I in the online-only Data Supplement). The identified ECM-related 
glycoproteins as well as their distribution and abundance in the input (GuHCl extracts), 
glycoprotein-enriched fraction and unbound flow-through are shown in Table III and Figure 
II in the online-only Data Supplement, respectively. In the glycoprotein-enriched fraction, 
levels of nidogen 2 and cadherin 2 were more abundant in LAA, whereas latent transforming 
growth factor-beta binding protein 4, fibulin 2, lumican and vitronectin were increased in 
RAA (Figure 1B). The latter findings were validated by immunoblotting of the original input 
material (Figure 1C and 1D).
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Next, we combined a direct MS/MS method with glycoprotein or glycopeptide enrichment 
strategies for the identification of the glycosylation sites (Figure 1A). In total, 65 N- and O-
linked glycosylation sites were identified in 35 extracellular proteins. Several known 
glycosylation sites were confirmed. In addition, putative and novel glycosylation sites were 
detected (Table IV in the online-only Data Supplement). Identified N-glycoforms were 
mostly complex, some sialylated or core fucosylated. Minor presences of high mannose and 
hybrid glycans were observed. O-linked glycans were predominantly core 1 or 2 types with 
or without sialic acid.
Decorin processing in cardiac atria
Upon enrichment for glycoproteins, decorin peptides were consistently identified in the flow 
through (Figure 2A). Decorin has three consensus sequences for N-glycosylation at 
asparagine (Asn) 211, Asn262 and Asn303. Unlike other SLRPs, all N-glycosylation sites 
within decorin are located at the C-terminal half of the protein (Figure 2B). Glycosylation of 
decorin was confirmed by sequential deglycosylation and direct confirmation of its 
glycosylation sites by MS/MS (Figure III in the online-only Data Supplement). A 
comparison of the sequence coverage revealed that only peptides from the non-glycosylated 
N-terminal half of decorin were identified in the flow-through. In contrast, peptides 
spanning the entire sequence were obtained in the input and the glycoprotein-enriched 
fraction (Figure 2C). Trypsin is commonly used for protein digestion prior to MS/MS. 
Identification of cleavage sites produced by enzymes other than trypsin (“non-tryptic 
cleavages”) can be indicative of proteolysis. Few ECM proteins displayed evidence for non-
tryptic cleavages (Table V in the online-only Data Supplement). For decorin, however, 18 
cleavage sites were detected (Figure 3A), and 11.9% of all spectra were non-tryptic (Figure 
IVA in the online-only Data Supplement). Despite >50% sequence homology to decorin, 
only 1.2% of spectra for biglycan were non-tryptic. A sequence alignment between decorin 
and biglycan revealed that most cleavage sites are within non-conserved regions (Figure IVB 
in the online-only Data Supplement), suggesting that sequence variation provides selectivity 
to the proteolytic processing of cardiac matricellular proteins.
Decorin processing is region specific
To investigate regional differences in decorin processing, decorin levels were compared 
between LAA and left ventricles (LV). Antibodies raised against three different decorin 
regions were used: the N-terminus (Ile36-Leu86), the internal part (Leu136-Ile215) and the 
C-terminus (Phe312-Lys359) of decorin (Figure 3B). All three antibodies recognised 
recombinant human decorin as well as decorin in human cardiac tissue (Figure 3C). In 
agreement with its predicted molecular weight (Mw), decorin protein core migrated as a 
~45-48 kDa doublet after removal of the glycosaminoglycan chain, but the three antibodies 
provided three different results (Figure 3C): according to the antibody recognizing the C-
terminus, decorin was reduced in LAA compared to LV. The antibodies to the internal and 
the N-terminal part of decorin, however, did not confirm this result, but revealed a Mw 
difference of ~3kDa between decorin in LAA (45kDa) and LV (48kDa). C-terminal 
truncation of decorin may explain this apparent discrepancy. The C-terminal region of 
decorin inhibits the activity of CTGF. At the protein level, CTGF was more abundant in LV 
than LAA (Figure 3C, bottom panel) despite reduced transcript levels (Figure VA in the 
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online-only Data Supplement). A search for putative protease targets on decorin using the 
PROSPER database returned cathepsins K and G as the most likely effectors (Figure VB in 
the online-only Data Supplement) for the prominent cleavage at the C-terminus observed at 
Phe330-Ser331 (Figure IVB in the online-only Data Supplement). Transcript levels for 
cathepsin K were higher in LAA compared to LV (Figure VC in the online-only Data 
Supplement). Taken together, these data suggest region-specific processing of decorin in the 
human cardiac ECM that may affect the local retention of growth factors.
Decorin cleavage in AF
AF, the most common arrhythmia encountered in clinical practice, results in significant 
morbidity and mortality. To provide insight into the consequences of persistent AF on 
decorin protein abundance, we compared LAA from patients in sinus rhythm (SR) with 
those with postoperative AF (SR-AF) and in persistent AF (Figure 4A, Figure VIA in the 
online-only Data Supplement). Table VI and Table VII in the online-only Data Supplement 
summarize their clinical characteristics. At the transcript level, there was no change of 
decorin or CTGF expression in AF patients and patients who developed post-operative AF 
compared to SR controls (Figure VIB in the online-only Data Supplement). At the protein 
level, however, the structural damage inflicted by prolonged AF was associated with higher 
levels of the full-length and the 45kDa forms of decorin (Figure 4B). The shift in the Mw by 
3kDa was similar to the one previously observed in LVs. Notably, CTGF protein levels were 
concurrently enhanced (Figure VIC in the online-only Data Supplement). Gene expression 
data using primers for the different regions of decorin support the notion that the processing 
of decorin occurs at the protein rather than the transcriptional level (Figure VID in the 
online-only Data Supplement). In contrast, decorin protein levels were found to be reduced 
in the SR-AF cohort compared to patients who maintained SR postoperatively (SR-SR) 
(Figure VII in the online-only Data Supplement).
Next, we interrogated the MS/MS data for potential cleavage sites.12 Non-tryptic peptides 
of decorin predominantly originated from four sites according to their absolute abundances: 
Val65-Gln66, Leu79-Pro80, Ser121-Pro122 and Phe330-Ser331. The latter cleavage site 
provides an explanation for the loss of detection with the antibody recognizing C-terminal 
epitopes. MS/MS spectra are shown in Figure VIIIA in the online-only Data Supplement, 
alongside elution times for the corresponding tryptic and non-tryptic peptides to exclude in-
source fragmentation. Notably, an additional cleavage site (Ser49-Leu50) was found in AF 
(Figure 4C). This cleavage site is next to a N-terminal domain that inhibits myostatin11, a 
negative regulator of muscle cell growth. According to the absolute and relative intensities 
(Figure VIIIB in the online-only Data Supplement), the non-tryptic decorin peptide 
generated by proteolytic cleavage at Ser49-Leu50 was higher in AF patients. Structurally, 
this part of decorin constitutes a natively disordered region13, which hindered further 
assessment of putative protease cleavage sites14 (Figure IX in the online-only Data 
Supplement).
Inhibition of myostatin activity
Myostatin gene expression was significantly reduced in AF patients (Figure 5A). Thus, we 
hypothesized that this processed form of decorin protein core generated during AF could 
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directly interfere with myostatin bioactivity. Myostatin inhibits phosphorylation of AMPK 
and activates SMAD2/3 (Figure 5B). Via the SMAD2/3 cascade, myostatin controls cell 
growth and differentiation. By inhibiting AMPK phosphorylation, myostatin alters cardiac 
metabolism. We synthesised peptides corresponding to the N-terminal peptides of mouse 
and human decorin (Figure XA in the online-only Data Supplement) and tested their activity 
in a reporter gene assay using HEK293-cells transfected with CAGA-luciferase plasmid. 
CAGA boxes are recognised by SMAD3 on the promoter regions of SMAD3-responsive 
genes, and therefore this technique screens SMAD3 activity. Incubation of transfected cells 
with 2.5nM myostatin triggered the activation of pathways downstream of the myostatin 
receptor as evidenced by increased luciferase activity. Addition of the synthetic N-terminal 
peptide (murine decorin AA 42-71, cleaved N-terminus) dose-dependently reduced this 
response (rho=-1.00, p<0.01) (Figure 5C). A longer decorin peptide (mouse AA 31-71, full 
N-terminus) was not as effective (rho=-0.83, p=0.04) (Figure XB in the online-only Data 
Supplement). Next, cell size was measured on isolated neonatal rat cardiomyocytes (Figure 
5D). The shorter N-terminal peptide mediated a strong repression of myostatin activity as 
evidenced by an increase in cell size upon hypertrophy stimuli (i.e. isoproterenol and 
phenylephrine) (Figure 5E and 5F; Figure XC in the online-only Data Supplement). Thus, 
decorin cleavage generates peptides with anti-myostatin activity.
Decorin null mice
The interaction of decorin with myostatin was further confirmed in hearts obtained from 
decorin null (DCN-/-) mice. Decorin deficiency resulted in a ≈50% reduction of myostatin 
expression (Figure 6A). Related ECM proteins showed no changes in abundance, but 
decorin deficiency was accompanied by a marked increase in SMAD2 phosphorylation 
(Figure 6B). Metabolic consequences of decorin deficiency were evident in metabolic 
profiles obtained by +H-NMR spectroscopy (Figure 6C; Figure XIA in the online-only Data 
Supplement). Levels of glutamine, succinate, aspartate and nicotinamide adenine 
dinucleotides (NAD+, NADH) were elevated in decorin null hearts, as compared to 
littermate controls (Figure 6D). In isolated cardiomyocytes, myostatin reduced AMPK 
phosphorylation, a master regulator for cardiac energy metabolism (Figure 6E). This 
myostatin effect was reversed by preincubation with decorin peptides corresponding to the 
myostatin-binding region in mouse and human (Figure 6F; Figure XIB and XIC in the 
online-only Data Supplement). A similar inhibitory effect of the N-terminal decorin peptide 
on myostatin signalling was observed in Langendorff hearts (Figure 6G and 6H; Figure XID 
in the online-only Data Supplement).
Discussion
By applying a novel proteomics approach to human atria, fundamental insights were 
obtained about the composition and the proteolytic processing of the human cardiac ECM, 
which has not been analyzed by proteomics thus far. Using proteomics in combination with 
metabolomics, we have previously shown that discordant metabolic alterations are evident in 
individuals susceptible to postoperative AF.4 We now identify endogenous decorin cleavage 
products in AF that may contribute to atrial remodelling and play a previously unrecognized 
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role in the susceptibility or perpetuation of arrhythmias by altering the local bioavailability 
of growth factors, such as CTGF and myostatin.
Glycoproteomics of the cardiac ECM
Thus far, proteomic studies of cardiac disease focussed mainly on evaluating differences in 
protein abundance4,5, in phosphorylation9,15 and in redox-modifications.16 However, 
alterations in glycosylation patterns and protein degradation are known to occur in disease.
17 Our study characterizes, for the first time, ECM proteins in human atria using state-of-
the-art glycoproteomics. Previously, Parker et al18 used glycoproteomics in rat hearts and 
characterised glycan composition after removal of the sugar moieties from the peptides. In 
this study, we analysed intact glycopeptides. Unlike conventional studies, in which ECM 
proteins are analysed by antibodies, proteomics does not require a priori decisions on which 
ECM proteins to study, and MS/MS is not dependent on the recognition of epitopes. 
Epitopes become masked i.e. by glycosylation or destroyed by proteolytic cleavage. These 
inherent constraints of antibody-based detection can lead to misinterpretations as 
demonstrated by the three immunoblots for decorin presented in Figure 3C.
Decorin and other SLRPs
Decorin is a member of SLRPs, a family of 18 structurally related ECM proteins. After 
synthesis, SLRPs are secreted into the extracellular space and exert diverse roles as 
biologically active regulators of the ECM.19 Similar to biglycan, decorin has a horseshoe 
shape and binds to collagen fibres to control their shape, size and distribution. Decorin and 
biglycan share >50% sequence identity, and have chemically similar amino acid 
substitutions at most other positions.20 Yet, decorin, but not biglycan, was subject to 
extensive proteolytic processing in human atria. Despite the structural and functional 
similarities of SLRPs, decorin is located in the interstitial ECM whereas biglycan is mainly 
associated to collagens in the pericellular regions.21 A sequence alignment between decorin 
and biglycan revealed that most cleavage sites in decorin mapped to non-conserved regions. 
Thus, specific cleavage sites might endow decorin with additional functional properties in 
the heart.
Biological activity of ECM cleavage products
Besides its role in ECM assembly, decorin has structural moieties that recognize not only 
collagens but also growth factors and cell surface receptors, affecting their activity and 
bioavailability.19,22 The regulatory mechanisms involve interactions with sugar residues or 
specific domains within the core protein.23 It is noteworthy that amongst all SLRPs, decorin 
had the highest number of non-tryptic cleavage sites, which were predominantly located on 
the N-terminal half of the protein. In general, the N-terminus and the C-terminus of SLRPs 
offer the highest variability for interaction partners.22 The decorin peptides within the N-
terminal half have anti-myostatin properties.11 An abundant cleavage site at the C-terminus 
(Phe330-Ser331) gives rise to a peptide with CTGF-binding properties.24 The known 
cleavage sites of decorin as well as the non-tryptic cleavages identified in atrial appendages 
and their relation to binding sequences for collagen and growth factors are summarized in 
Figure XII in the online-only Data Supplement.
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C-terminal decorin peptides bind CTGF
The C-terminal tail of decorin, also known as the cysteine-rich “ear”, is involved in ligand-
binding regulation and conformational stability via two cysteines at positions 313 and 346. 
A point mutation within this region is the genetic cause for congenital hereditary stromal 
dystrophy of the cornea and linked to abnormal fibrillogenesis.25 The abundant cleavage site 
at position Phe330-Ser331 results in a truncated form of decorin (loss of 3 kDa). C-terminal 
truncation of decorin was predominantly observed in LAA and to a lesser extent in LV. 
Importantly, a synthetic decorin peptide within LRR12 (i.e. Gln335-Lys359) has been shown 
to bind CTGF and attenuate fibrosis.24 Thus, C-terminal truncation may result in 
diminished collagen-binding ability and repression of CTGF activity in human atria with 
their lower mechanical load and decreased stiffness compared to LV (Figure 7).
N-terminal decorin peptides regulate myostatin
At the N-terminus, four cysteine residues form a disulfide knot (Cys54-Cys60 and Cys58-
Cys67) that buries the hydrophobic core of the first leucine-rich repeat (LRR1). Binding of 
Zn2+ to this region results in a conformational change required for myostatin binding.26 
Equivalent biglycan moieties do not bind myostatin.26,27 Myostatin, a potent antagonist to 
hypertrophic stimuli28, is synthesized as inactive protein with a N-terminal propeptide. 
After activation, myostatin is regulated via non-covalent binding to its propeptide, forming a 
latent complex.29 Our experiments demonstrated a markedly lower expression of myostatin 
in hearts of decorin null mice, supporting the notion of a myostatin-decorin feedback loop. 
In cardiomyocytes, myostatin regulates at least two pathways downstream of the activin 
receptor (Figure 5B): (i) Co-incubation of myostatin with the N-terminal decorin peptide 
lead to inhibition of SMAD2/3 activity in a dose-dependent manner. SMAD3 activation via 
myostatin represses muscle cell growth.30 When cardiomyocytes were treated with 
increasing concentrations of the N-terminal decorin peptide, the effect of myostatin on cell 
size was reversed. In line with these in vitro findings, SMAD2 phosphorylation was 
increased in hearts of decorin null mice. (ii) By inhibiting AMPK phosphorylation via 
activin receptor and TAK1, myostatin regulates cardiac energy homeostasis.31 AMPK is a 
crucial energy sensor with a phosphorylation site in its activation loop at threonine 172 
(Thr172).32 In in vitro and ex vivo experiments, both the murine and the human N-terminal 
peptides of decorin maintained phosphorylation of AMPK at Thr172 in the presence of 
myostatin. In hearts of decorin null mice, with reduced myostatin levels, NMR spectroscopy 
profiling revealed changes in metabolites linked to mitochondrial metabolism and an 
accumulation of nicotinamide adenine dinucleotides. Activation of AMPK increases ATP 
production mostly by enhancing oxidative metabolism leading to a gradual increase in 
NAD+ levels as a consequence of fatty acid oxidation.33
Decorin in patients with AF
In human AF, we observed an additional decorin cleavage site next to the myostatin-binding 
region (Figure 7, position Ser49-Leu50).11 This cleavage site generates a decorin form 
devoid of the glycosaminoglycan chain at Ser34.14 We demonstrated that the resulting 
peptide suppresses myostatin activity and increases cardiomyocyte size. Notably, in a goat 
model of pacing-induced AF, changes in cellular substructures were accompanied by an 
Barallobre-Barreiro et al. Page 9
Circulation. Author manuscript; available in PMC 2017 March 13.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
increase in myocyte size (up to 195%).34 The additional cleavage site in AF releases decorin 
peptides that only contain the myostatin-binding region and are therefore less likely to 
interact with other binding partners. In comparison to other regulators of myostatin activity, 
i.e. myostatin propeptide and follistatin35, decorin is abundant and readily available within 
the cardiac ECM. Thus, its cleavage products may constitute an important local regulatory 
mechanism of myostatin activity.
Evidence in preclinical models
Inhibition of myostatin by cardiac-specific overexpression of the myostatin propeptide 
induced enlarged atria and AF in the transgenic mice.36 Similarly, mice overexpressing 
microRNA-208a, a “myomiR” enriched in hearts, developed spontaneous AF. Besides 
thyroid hormone receptor-associated protein 1, myostatin was identified as a regulatory 
target of microRNA-208a.37 Similarly, AMPK signalling, one of the key downstream 
signalling pathways of myostatin, has been implicated as a mechanism for AF in mice with 
cardiac-specific deletion of liver kinase B1.38 Taking together, these data provide in vivo 
evidence that loss of myostatin activity and dysregulation of AMPK signaling can act as a 
substrate for AF, at least in mice.
Study limitations
Our proteomics findings in clinical samples do not directly prove a decorin-mediated effect 
on atrial myostatin signaling. While local injection of decorin peptides in skeletal muscle 
increased muscle mass11, in vivo studies are required to further explore the role of decorin 
cleavage products in cardiac disease, i.e. the specificity of the interaction and the location of 
the effects. Decorin has many binding partners.8 Thus, the genetic deletion of decorin in 
mice may have pleiotropic effects. Lectin enrichment of glycoproteins presents selectivity 
bias towards specific glycoforms, and high Mw glycoproteins in basement membranes, i.e. 
collagens, laminins, and perlecan, are barely re-solubilised by buffers compatible with the 
affinity enrichment of glycoproteins. The direct glycopeptide method employed in this study 
identifies the peptide sequence, the glycosite, and the glycan mass but the glycan 
composition is only calculated based on accurate mass and the glycan structure remains 
unresolved. Emerging technologies combining MS with glycan structural data are yet to be 
applied to the human and cardiac contexts.39 Moreover, non-tryptic cleavage sites at 
positions containing lysine or arginine will be missed by digestion with trypsin. Advances in 
positional proteomics will help to better characterize proteolytic cleavage in cardiac disease.
40
Conclusions
The glycoproteomic analysis of atrial appendages allowed, for the first time, a detailed 
analysis of human cardiac ECM proteins. It examined differences in the ECM composition 
between RAA and LAA; confirmed putative and revealed new glycosylation sites in the 
cardiac ECM; and identified decorin-derived cleavage products that can act as local 
regulators of growth factor activity. Proteomic workflows, as outlined in this study, will be 
essential to explore the different aspects of ECM remodelling in cardiovascular disease, as 
exemplified by the observed changes in decorin processing during structural remodelling in 
persistent AF.
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Clinical Perspective
What is new?
• We used proteomics to analyse the extracellular matrix in human atrial 
appendages. By using novel mass spectrometry methods, we provide 
the first comprehensive characterisation of human cardiac extracellular 
matrix proteins, including the identification of glycosylation sites.
• We found that decorin, a small and leucine-rich proteoglycan, is 
truncated in atria compared to ventricles resulting in the loss of the 
binding site for connective tissue growth factor. In atrial fibrillation, 
decorin is increased but an additional cleavage site gives rise to 
peptides with myostatin-binding properties. These decorin peptides 
antagonize myostatin.
What are the clinical implications?
• Atrial fibrillation is the most common arrhythmia encountered in 
clinical practice and myostatin inhibition has been implicated as a 
substrate for atrial fibrillation. Myostatin expression was reduced in 
patients with atrial fibrillation and in hearts from decorin null mice.
• Peptides generated from the cleavage of extracellular matrix proteins 
such as decorin constitute a local regulatory mechanism for the 
bioactivity and bioavailability of growth factors in human cardiac 
tissue.
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Figure 1. Glycoproteomics of the human cardiac ECM.
A) Atrial appendages were collected from patients in SR during cardiac surgery and subject 
to a decellularization-based three-step extraction for ECM proteins. First, GuHCl extracts 
were analyzed by LC-MS/MS. Then, ECM extracts were enriched for glycoproteins. The 
glycoprotein-enriched and unbound flow-through fractions were analysed by LC-MS/MS. 
Finally, enrichment was performed for glycoproteins as well as glycopeptides for direct 
glycopeptide identification by LC-MS/MS. B) Comparison of ECM-related glycoproteins in 
LAA and RAA (n=5, each). LTBP4 denotes latent transforming growth factor-beta binding 
protein 4; VTNC, vitronectin; FBLN2, fibulin 2; LUM, lumican; NID2, nidogen 2; CADH2, 
cadherin 2; BCAM, basal cell adhesion molecule. C) Validation by immunoblotting. 
Biglycan, mimecan (MIME) and Coomassie staining were included as controls. D) 
Quantification by densitometry. Bars represent mean ± SD. **p<0.01; ***p<0.001; A.U., 
arbitrary units.
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Figure 2. Decorin after glycoprotein enrichment.
A) Proteomic comparison of the glycoprotein-enriched fraction and the flow-through. 
Relative abundances of glycoproteins (red dots) and non-glycosylated proteins (blue dots) 
are plotted for LAA and RAA (n=5, each). Decorin was the only glycoprotein consistently 
detected among the non-glycosylated proteins in the flow-through (yellow dots). B) The C-
terminal half of decorin has three N-glycosylation sites (red triangles). C) According to the 
sequence coverage (yellow colour) in the three different fractions (input, glycoprotein-
enriched fraction, non-glycosylated flow-through), only N-terminal (non-glycosylated) 
decorin peptides were identified in the flow-through.
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Figure 3. Decorin processing in atrial tissue.
A) Decorin (DCN) showed the highest number of non-tryptic cleavage sites among all ECM 
proteins identified. Biglycan (BGN) is highlighted for comparison. B) Three different 
antibodies recognizing different epitopes were used to detect decorin. Numbers indicate 
amino acid positions. C) Comparison of LAA and LV. Note the C-terminal truncation of 
decorin in LAA compared to LV from non-failing hearts (Mw shift from 48kDa to 45kDa). 
The apparent reduction of decorin levels in LAA with the C-terminal antibody was not 
corroborated by antibodies to N-terminal and internal epitopes. Instead, they revealed a loss 
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of ~3kDa in LAA compared to LV. Biglycan, a highly homologous SLRP, showed no such 
shift in Mw. The graphs show the densitometry results from immunoblots based on 
antibodies against three different decorin epitopes. Bars represent mean ± SD. A.U., 
arbitrary units.
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Figure 4. Decorin processing in AF.
A) Representative pre-operative and postoperative echocardiography images from patients 
who stayed in SR throughout surgery and patients who developed postoperative AF. 
Rightmost panels depict left atrial structural remodeling observed in a patient with 
permanent, chronic AF after a 5-year follow-up. B) Immunoblotting for decorin in GuHCl 
extracts from LAA samples. Decorin was more abundant in AF than SR patients, and both 
bands (C-terminally truncated decorin at 45kDa and full-length at 48kDa) became 
detectable. The bottom chart shows the quantification (mean ± SD) in SR and AF patients 
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(n=6, each) with the antibody against the internal region. **p<0.01 C) GuHCl extracts (n=6, 
each group) were analysed using LC-MS/MS. After a search using no enzyme, non-tryptic 
decorin peptides were identified and quantified. In addition to the four main cleavage sites of 
decorin in SR, a N-terminal cleavage site at position Ser49-Leu50 was detected in AF.
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Figure 5. Decorin peptides bind myostatin.
A) qPCR analysis for myostatin expression in additional samples (SR-SR=14, SR-AF=10, 
AF=13). Bars represent mean ± SD. B) Schematic illustration of two downstream signaling 
pathways of myostatin (MSTN). “ActRIIB/ALK” denotes Activin receptor type-2B 
(ActRIIB)/ activin receptor-like kinase (ALK) receptor complex; “TAK1” transforming 
growth factor beta-activated kinase 1. C) Repression of MSTN-SMAD3 signaling. A 
synthetic N-terminal peptide of mouse decorin (amino acids 42-71 corresponding to the 
peptide generated by the Ser49-Leu50 cleavage site in humans) inhibited the CAGA-
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luciferase reporter activity in a dose-dependent manner. The trend for the effect was 
calculated based on Spearman’s correlation (rho, ρ). Bars are mean ± SD of triplicate 
experiments. D) Effect on rat cardiomyocytes. MSTN represses hypertrophy induced by pre-
treatment with isoproterenol (Iso) and phenylephrine (PE). Cardiomyocyte size is given as 
mean ± standard error of the mean (SEM). E) Cardiomyocyte size was calculated after 
defining the cell perimeter to integrate the area (see bottom panels). F) The decorin N-
terminal peptide attenuated the MSTN effect dose-dependently (0-20µM). Cardiomyocyte 
size is given as mean ± SEM based on a total of 300-400 cell measurements per 
experimental condition and compared to a control without decorin N-terminal peptide. 
*p<0.05; ***p<0.001.
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Figure 6. Effect of decorin on cardiac metabolism.
A) Deficiency of decorin was associated with reduced expression of myostatin in murine 
hearts. Bars represent mean ± SD. B) In hearts of decorin null mice, the abundance of 
closely related SLRPs, such as biglycan and lumican (LUM) was not affected, but 
phosphorylation of SMAD2 was increased. C) Overlay of +H-NMR spectra from wild type 
and decorin null (DCN -/-) hearts. D) Metabolic profiles of cardiac tissue from DCN -/- mice 
revealed elevated levels of glutamine (Gln), succinate (Suc), aspartate (Asp) and 
nicotinamide adenine dinucleotides (NAD+, NADH). E) Myostatin represses AMPK 
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activation in rat cardiomyocytes. Immunoblotting was performed with two different 
antibodies for AMPK phospho-Thr172. Levels of total AMPK (pan-AMPK) were 
unchanged. F) N-terminal decorin peptides from mouse or human origin (20µM) reversed 
the effect of myostatin on AMPK phosphorylation. Rat cardiomyocytes were stimulated 
with Iso and PE after incubation with myostatin for 2 hours. G) Schematic summary of the 
experiment in Langendorff perfused mouse hearts. H) Phosphorylation levels of AMPK and 
SMAD2 were used as readouts for inhibition of myostatin signaling by the N-terminal 
decorin peptide. **p<0.01; ***p<0.001.
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Figure 7. Decorin in human atria.
Decorin cleavage constitutes a mechanism for local regulation of growth factor bioactivity in 
the human cardiac ECM. N-terminal cleavage of decorin was observed in patients with 
persistent AF and gives rise to peptides with anti-myostatin activity. C-terminal truncation is 
more common in atria than ventricles and releases the CTGF-binding domain of decorin.
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Table 1
Identification of ECM and ECM-Associated Proteins in Human Atrial Appendages
Proteins (97) GuHCl (Input) Glycoprotein Enrichment Glycopeptide Analysis
Alpha-1-acid glycoprotein 1 + +
Alpha-1-acid glycoprotein 2 +
Alpha-1B-glycoprotein + +
Alpha-2-HS-glycoprotein + +
Annexin A2 +
Apolipoprotein A-I +
Apolipoprotein A-IV + +
Apolipoprotein C-III +
Apolipoprotein E +
Asporin +
Basal cell adhesion molecule + + +
Beta-2-glycoprotein 1 + + +
Biglycan +
Cadherin-13 +
Cadherin-2 + + +
Cartilage intermediate layer protein 1 +
Cartilage oligomeric matrix protein +
Cathepsin G +
Chymase +
Clusterin + + +
Collagen alpha-1(I) +
Collagen alpha-1(II) +
Collagen alpha-1(III) +
Collagen alpha-1(IV) + +
Collagen alpha-1(V) +
Collagen alpha-1(VI) + +
Collagen alpha-1(VIII) +
Collagen alpha-1(XV) +
Collagen alpha-1(XVIII) + +
Collagen alpha-1(XXVIII) + +
Collagen alpha-2(I) + +
Collagen alpha-2(IV) + +
Collagen alpha-2(V) +
Collagen alpha-2(VI) + +
Collagen alpha-3(V) +
Collagen alpha-3(VI) + + +
Collagen alpha-6(VI) + +
Decorin + + +
Dermatopontin +
Circulation. Author manuscript; available in PMC 2017 March 13.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Barallobre-Barreiro et al. Page 27
Proteins (97) GuHCl (Input) Glycoprotein Enrichment Glycopeptide Analysis
Dystroglycan + +
Elastin +
EMILIN-1 +
Extracellular superoxide dismutase +
Fibrillin-1 + +
Fibromodulin +
Fibronectin + +
Fibulin-2 + +
Galectin-1 +
Galectin-3 +
Galectin-3-binding protein + +
Glypican-1 +
Hepatoma-derived growth factor +
Insulin-like growth factor-binding protein 7 +
Intercellular adhesion molecule 1 +
Kininogen-1 +
Lactadherin +
Laminin subunit alpha-2 +
Laminin subunit alpha-4 +
Laminin subunit alpha-5 +
Laminin subunit beta-1 +
Laminin subunit beta-2 + + +
Laminin subunit gamma-1 + +
Latent-TGFβ-binding protein 2 +
Latent-TGFβ-binding protein 4 +
Leukocyte elastase inhibitor +
Lumican + + +
Mast cell carboxypeptidase A +
Matrix Gla protein +
Matrix-remodeling-associated protein 7 +
Metalloproteinase inhibitor 3 +
Mimecan + + +
Natriuretic peptide A +
Neural cell adhesion molecule 1 +
Neural cell adhesion molecule L1 + + +
Neutrophil defensin 1 +
Nidogen-1 + + +
Nidogen-2 + +
Periostin +
Perlecan + +
Podocan +
Proactivator polypeptide +
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Proteins (97) GuHCl (Input) Glycoprotein Enrichment Glycopeptide Analysis
Prolargin + + +
Protein AMBP +
Proteoglycan 4 + +
RPE-spondin +
Secreted frizzled-related protein 1 +
Secreted phosphoprotein 24 + +
Serum amyloid P-component + + +
Target of Nesh-SH3 + +
Tenascin +
Tenascin-X + + +
TGFβ-induced protein ig-h3 +
Tryptase beta-2 +
Tubulointerstitial nephritis antigen-like + +
Versican + + +
Vitronectin + + +
Zinc-alpha-2-glycoprotein +
+ denotes identification by one of the three proteomics strategies
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